• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cytek Biosciences Set to Join S&P SmallCap 600

    4/25/23 5:54:00 PM ET
    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ABT alert in real time by email

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    May 1, 2023

    S&P SmallCap 600

    Addition

    Cytek Biosciences

    CTKB

    Health Care



    S&P SmallCap 600

    Deletion

    Cardiovascular Systems

    CSII

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/cytek-biosciences-set-to-join-sp-smallcap-600-301807529.html

    SOURCE S&P Dow Jones Indices

    Get the next $ABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABT
    $CSII
    $CTKB
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    Cytek Biosciences Inc.
    $CTKB
    12/2/2025$6.00Equal-Weight
    Morgan Stanley
    Abbott Laboratories
    $ABT
    10/10/2025$145.00Buy
    The Benchmark Company
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    Abbott Laboratories
    $ABT
    7/18/2025$145.00Hold → Buy
    Jefferies
    Abbott Laboratories
    $ABT
    6/16/2025$143.00Market Perform
    Leerink Partners
    Cytek Biosciences Inc.
    $CTKB
    5/9/2025$4.00Buy → Hold
    TD Cowen
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    More analyst ratings

    $ABT
    $CSII
    $CTKB
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 24, 2023 - FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes

    For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

    10/24/23 3:52:17 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    SEC Filings

    View All

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/16/25 4:05:25 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott Laboratories filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ABBOTT LABORATORIES (0000001800) (Filer)

    12/12/25 4:10:48 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/4/25 4:16:26 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Joly Hubert claimed ownership of 165 shares (SEC Form 3)

    3 - S&P Global Inc. (0000064040) (Issuer)

    1/9/26 4:02:02 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Director Washington Gregory N

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/6/26 4:10:32 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Director Morris Maria R

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/6/26 4:09:42 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Schedules Fourth Quarter and Full-Year 2025 Earnings Announcement and Conference Call for Tuesday, February 10, 2026

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- S&P Global's (NYSE: SPGI) fourth quarter and full-year 2025 results will be issued on Tuesday, February 10, 2026 via news release at approximately 7:15 a.m. Eastern Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Time on February 10, 2026 to discuss the Company's fourth quarter and full-year 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, sup

    1/9/26 2:42:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    'Substantial Shortfall' in Copper Supply Widens as the Race for AI and Growing Defense Spending Add to Accelerating Demand, New S&P Global Study Finds

    Supply deficit would reach 10 million metric tons by 2040 as demand surges 50% WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- A looming copper supply gap is poised to widen as electricity demand accelerates and new vectors—such as the race for artificial intelligence and surging defense spending—add to the call on copper. According to Copper in the Age of AI: The Challenges of Electrification, a comprehensive new study by S&P Global (NYSE:SPGI), the emerging supply deficit constitutes a "systemic risk for global industries, technological advancement and economic growth." The study f

    1/8/26 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott's FreeStyle Libre 3 Plus Now Covered Across Canada

    Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently,iAbbott's latest innovation, the FreeStyle Libre 3 Plus* sensor, is easy to apply, ii easy to useiii and features the world's smallest glucose sensor, iv,v providing users with accurate and consistent glucose readings for up to 15 days.i,vMISSISSAUGA, ON, Jan. 7, 2026 /CNW/ -- Abbott's (NYSE:ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across Canadavi, in federal plans like Non-Insured Health Benefits (NIHB)vi and by a majority of employer-sponsored wo

    1/7/26 9:00:00 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

    4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

    6/3/25 5:39:17 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Cytek Biosciences with a new price target

    Morgan Stanley resumed coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $6.00

    12/2/25 8:24:49 AM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    The Benchmark Company initiated coverage on Abbott Labs with a new price target

    The Benchmark Company initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $145.00

    10/10/25 8:35:50 AM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600

    NEW YORK, Dec. 23, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:  UiPath Inc. (NYSE:PATH) will replace Synovus Financial Corp. (NYSE:SNV) in the S&P MidCap 400 effective prior to the opening of trading on Friday, January 2. S&P MidCap 400 constituent Pinnacle Financial Partners Inc. (NASD: PNFP) is acquiring Synovus Financial Corp in a deal expected to be completed soon, pending final closing conditions.Versant Media Group Inc. (NASD: VSNT) will replace Brandywine Realty Trust (NYSE:BDN) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 6. S&P 500 constituent Comcast Corp. (NASD: CMCSA)

    12/23/25 5:55:00 PM ET
    $BDN
    $CMCSA
    $PATH
    Real Estate Investment Trusts
    Real Estate
    Cable & Other Pay Television Services
    Telecommunications

    S&P Global Adds Hubert Joly to its Board of Directors

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today that its Board of Directors has approved the addition of Mr. Hubert Joly to the Board, effective January 2, 2026. Mr. Joly is the former Chair and Chief Executive Officer at Best Buy and is now a senior lecturer at Harvard Business School. Earlier in his career, Mr. Joly served as President and CEO of Carlson, a global hospitality and travel company. In addition to his teaching post at Harvard, Mr. Joly is a member of the Board of Directors of Johnson & Johnson and was until recently on the Board of

    12/16/25 8:05:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Announces Mobility Business Chief Financial Officer

    Matt Calderone, outgoing CFO of Booz Allen, named new CFO of Mobility and will lead the finance function of the standalone company NEW YORK, Dec. 16, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Matt Calderone as Chief Financial Officer (CFO) of the Mobility business, joining the company by March 1, 2026. Mr. Calderone will serve as the CFO of the standalone public company through its planned separation from S&P Global and will oversee all aspects of the company's Finance function. He will report to Mr. Bill Eager, President of S&P Global Mobility, and CEO-designate of the future standalone company.

    12/16/25 7:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ABT
    $CSII
    $CTKB
    $SPGI
    Financials

    Live finance-specific insights

    View All

    S&P Global Schedules Fourth Quarter and Full-Year 2025 Earnings Announcement and Conference Call for Tuesday, February 10, 2026

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- S&P Global's (NYSE: SPGI) fourth quarter and full-year 2025 results will be issued on Tuesday, February 10, 2026 via news release at approximately 7:15 a.m. Eastern Time. The news release will be available at www.spglobal.com. Martina Cheung, President and CEO; Eric Aboaf, Chief Financial Officer; and Mark Grant, Senior Vice President, Investor Relations and Treasurer, will host a conference call and webcast at 8:30 a.m. Eastern Time on February 10, 2026 to discuss the Company's fourth quarter and full-year 2025 financial results. The presentation is open to all interested parties and may include forward-looking information. The presenters' slides, sup

    1/9/26 2:42:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Reports U.S. Common Indicated Dividend Payments Increase of $13.1 Billion in Q4 2025 and $46.4 Billion for 2025

    Q4 2025 U.S. common dividend increases were $16.1 billion, up 14.9% from $14.0 billion in Q3 2025 and up 13.0% from $14.2 billion in Q4 2024.Q4 2025 U.S. common dividend decreases were $3.0 billion, down 12.4% from $3.4 billion in Q3 2025 and up 20.5% from $2.5 billion in Q4 2024.Q4 2025 net indicated dividend rate change increased $13.1 billion. For 2025 U.S. common dividend increases were $59.3 billion, down 16.9% from the 2024 period's $71.4 billion; decreases were down 28.8% to $12.9 billion compared to $18.1 billion for the prior 12-month period.The net 2025 indicated dividend increase was $46.4 billion compared to $45.1 billion for the 12-months ending September 2025 and $53.3 billion

    1/7/26 9:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Abbott hosts conference call for fourth-quarter earnings

    ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica

    1/5/26 4:30:00 PM ET
    $ABT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABT
    $CSII
    $CTKB
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 4:35:51 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

    SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

    11/14/24 1:42:15 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Cytek Biosciences Inc.

    SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

    2/22/24 7:07:27 PM ET
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials